Amphastar Pharmaceuticals (AMPH) Tax Provisions (2013 - 2026)

Amphastar Pharmaceuticals has reported Tax Provisions for 14 years, with the latest figure at $8.2 million in Q2 2026.

• On a quarterly basis, Tax Provisions fell 1.31% year-over-year to $8.2 million in Q2 2026; TTM through Jun 2026 was $23.9 million, a 46.0% decrease from a year earlier, with the FY2025 full-year figure at $26.0 million, down 44.54% from the prior year.
• Tax Provisions was $8.2 million for Q2 2026 at Amphastar Pharmaceuticals, up from $3.6 million in the prior quarter.
• The five-year high for Tax Provisions was $23.2 million in Q4 2022, with the low at $3.6 million in Q1 2026.
• Average Tax Provisions over 5 years is $9.4 million, with a median of $7.0 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Tax Provisions soared 252.99% in 2022, then plunged 65.79% in 2025.
• Over 5 years, Tax Provisions stood at $23.2 million in 2022, then retreated by 20.02% to $18.5 million in 2023, then climbed by 24.88% to $23.1 million in 2024, then slumped by 65.79% to $7.9 million in 2025, then climbed by 3.54% to $8.2 million in 2026.
• The last three Tax Provisions figures came in at $8.2 million (Q2 2026), $3.6 million (Q1 2026), and $7.9 million (Q4 2025), per Business Quant data.